Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

PURPOSE OF REVIEW: Checkpoint inhibitors (CPIs) targeting PD1 are highly active in relapsed/refractory classical Hodgkin lymphoma. A plethora of recent studies, often small and non-randomised, have raised many questions about how to optimally integrate these into clinical practice. We aim to discuss...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiao-Yin, Collins, Graham P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Lymphomas (T Hilal, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606050/
https://www.ncbi.nlm.nih.gov/pubmed/35696020
http://dx.doi.org/10.1007/s11912-022-01292-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606050/
https://www.ncbi.nlm.nih.gov/pubmed/35696020
http://dx.doi.org/10.1007/s11912-022-01292-2

Ejemplares similares